| DOI: | 10.2172/1060004
|
| 报告号: | DE-FG02-08ER64670-1
|
| 报告题名: | Development of Biomarkers for Chronic Beryllium Disease in Mice |
| 作者: | Gordon, Terry
|
| 出版年: | 2013
|
| 发表日期: | 2013-01-25
|
| 国家: | 美国
|
| 语种: | 英语
|
| 英文关键词: | beryllium biomarkers
|
| 英文摘要: | Beryllium is a strategic metal, indispensable for national defense programs in aerospace, telecommunications, electronics, and weaponry. Exposure to beryllium is an extensively documented occupational hazard that causes irreversible, debilitating granulomatous lung disease in as much as 3 - 5% of exposed workers. Mechanistic research on beryllium exposure-disease relationships has been severely limited by a general lack of a sufficient CBD animal model. We have now developed and tested an animal model which can be used for dissecting dose-response relationships and pathogenic mechanisms and for testing new diagnostic and treatment paradigms. We have created 3 strains of transgenic mice in which the human antigen-presenting moiety, HLA-DP, was inserted into the mouse genome. Each mouse strain contains HLA-DPB1 alleles that confer different magnitude of risk for chronic beryllium disease (CBD): HLA-DPB1*0401 (odds ratio = 0.2), HLA-DPB1*0201 (odds ratio = 15), HLA-DPB1*1701 (odds ratio = 240). Our preliminary work has demonstrated that the *1701 allele, as predicted by human studies, results in the greatest degree of sensitization in a mouse ear swelling test. We have also completed dose-response experiments examining beryllium-induced lung granulomas and identified susceptible and resistant inbred strains of mice (without the human transgenes) as well as quantitative trait loci that may contain gene(s) that modify the immune response to beryllium. In this grant application, we propose to use the transgenic and normal inbred strains of mice to identify biomarkers for the progression of beryllium sensitization and CBD. To achieve this goal, we propose to compare the sensitivity and accuracy of the lymphocyte proliferation test (blood and bronchoalveolar lavage fluid) with the ELISPOT test in the three HLA-DP transgenic mice strains throughout a 6 month treatment with beryllium particles. Because of the availability of high-throughput proteomics, we will also identify changes in potential protein biomarkers in beryllium-treated mice. We will correlate these findings with the ability of the transgenic mice to develop a beryllium-specific adaptive immune response in blood and bronchoalveolar lavage (BAL) fluid. We will also determine whether beryllium-responsive CD4+ T cells in blood and BAL correlate with the onset of granuloma formation. Thus, we will provide the scientific community with biomarkers of sensitization and disease progression for CBD. These biomarkers will serve as critical tools for development of improved industrial hygiene and therapeutic interventions. |
| URL: | http://www.osti.gov/scitech/servlets/purl/1060004
|
| Citation statistics: |
|
| 资源类型: | 研究报告
|
| 标识符: | http://119.78.100.158/handle/2HF3EXSE/41282
|
| Appears in Collections: | 过去全球变化的重建
影响、适应和脆弱性
科学计划与规划
气候变化与战略
全球变化的国际研究计划
气候减缓与适应
气候变化事实与影响
|
| File Name/ File Size |
Content Type |
Version |
Access |
License |
|
|---|
| 1060004.pdf（61KB） | 研究报告 | -- | 开放获取 | | View
Download
|
|
| Recommended Citation: | |
Gordon, Terry. Development of Biomarkers for Chronic Beryllium Disease in Mice. 2013-01-01.
|
|
|